Adir Et Compagnie

Centre National De La Recherche Scientifique

Université Paris—sud

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Les Laboratoires Servier

Adir Et Cie

Hopital Marie Lannelongue

Université Paris-saclay

Université De Paris

Jean-Daniel Brion

Luc Demuynck

Jacqueline Bonnet

Samir Messaoudi

Lucy De Montarby

Guillaume Le Baut

Yves Rolland

Mouad Alami

Jean-Gilles Parmentier

Armel Fradin

Jérôme Bignon

Pietro Ghezzi

Anne-Marie Chollet

Pierre Lestage

Pierre Potier

Jean Lepagnol

Claude Thal

Gilles Bru-Mercier

Marc Humbert

Abdallah Hamze

Gilles Galvani

Olivier Provot

Pascal Schmitt

Mark Millan

Frédéric Le Strat

Sylvia Cohen-Kaminsky

Guillaume Poissonnet

Mouâd Alami

Patrick Ducrey

Sylvie Piessard-Robert

Genevieve Seurre

Joëlle Dubois

Jean-Francedillaois Pujol

Anne Dekeyne

Jean Albert Boutin

Joanna Bakala

Massimo Sabatini

Solo Goldstein

Charles Tordjman

Claude Cudennec

Alain Le Ridant

Sebastien Dumas

Catherine Harpey

Zafiarisoa Dolor Renko

Jian-Miao Liu

Larbi Belachmi

Mohamed-Ali Soussi

Lucien Israel

Joanna Bakala-Wdzieczak

Cherif Rabhi

Sébastien Dumas

El Bachir Kaloun

Anne Moreau

Jean-François Peyrat

Anne Giraud

Maud Hervet

Christophe Galtier

The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists. 

Dizocilpine derivatives as peripheral NMDA receptor antagonists

The present invention relates to the design of novel molecules, referred to as 'multi-target' molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the 'multi-target' molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one &#x201c;multi-target&#x201d; molecule, and the use of such compositions in the treatment of cancer.

'Multi-target' compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer

The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Cytotoxic compounds which are inhibitors of the polymerisation of tubulin

The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists. 

Adamantane and memantine derivatives as peripheral NMDA receptor antagonists

The invention relates to a compound of the formula (I) in which: R, Rand Rare independently a methoxy group optionally substituted by one or more fluorine atoms; Ris a hydrogen atom; Rand Rare identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Iso CA-4 and analogues thereof as potent cytotoxic agents inhibiting tubuline polymerization

Compound of formula (I): wherein: Medicinal products containing the same which are useful as anti-cancer agents.

3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same

Beta-carboline compounds

A compound of formula (I): ##STR1## in which X, n, B and Y are as defined in the description. useful as cytokine inhibitors.

Heterocyclic compounds

A compound selected from those of general formula (I): ##STR1## wherein A represents a bivalent radical ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and Z are as defined in the description, the isomers and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of depression and anxiety.

Benzopyrrolizinoquinolizinones

A compound selected from those of general formula (I): ##STR1## wherein A represents a bivalent radical selected from ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and Z are as defined in the description,

EburnanE analogues

New benzothiazine derivatives corresponding to the general formula I: ##STR1## in which: X represents halogen,

Phenothiazine cytokine inhibitors

A compound selected from those of formula (I): ##STR1## in which the groups R.sub.1 to R.sub.8 are as defined the description. Medicaments.

New chromene compounds having a triene side chain

Compounds of general formula (I): ##STR1## in which: R denotes a hydrogen atom, a halogen atom or a hydroxy, lower alkyl, lower alkyloxy, carboxyl, (lower alkyloxy)carbonyl, (lower arylalkyloxy)carbonyl, aminocarbonyl, (lower mono- or dialkyl)aminocarbonyl or (lower arylalkyl)aminocarbonyl group, an aminocarbonyl group N-substituted with a heterocyclic radical, or a thio, (lower alkyl)thio, sulfonyl or (lower alkyl)sulfonyl group,

New heteroarotinoid compounds

Compounds of general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be identical or different, denote a hydrogen atom, a halogen atom or a lower alkyl, lower alkenyl, lower alkyloxy or lower alkenyloxy group, optionally substituted with one or more halogen atoms,

Triene compounds having a chromene structure

Growing community of inventors

Saint Leu la Foret, France

Jean-Daniel Brion